Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
A group of senators this week reintroduced a bill titled “The Interagency Patent Coordination and Improvement Act,” which ...
The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...
Addressing the calculation of patent term extensions (PTEs) under the Hatch-Waxman Act, the US Court of Appeals for the Federal Circuit affirmed ...
Delhi HC rejects interim injunction plea from Roche against Natco's SMA drug Evrysdi: Our Bureau, New Delhi Thursday, March 27, 2025, 08:00 Hrs [IST] The Delhi High Court has reje ...
For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...
2d
Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...
2d
The global Drug Discovery Services Market , valued at US$14.89 billion in 2024, is forecasted to grow at a robust CAGR of ...
It’s no wonder CPRX shares are up 23% this year – and they could rise more. MAPsignals data shows how Big Money investors are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback